Qurient FY 2025 Annual ReportBeta
Qurient annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Qurient FY 2025 Annual Report Analysis
Business Overview
- • 2025 consolidated revenue KRW 6.98B, down from KRW 9.18B in 2024, driven by drug distribution and R&D service revenue
- • 2025 R&D expenses KRW 21.52B, R&D to sales ratio 327.64%, up from 222.60% in 2024
Management Discussion & Analysis
- • Revenue KRW 6.98B (-24% YoY), operating loss KRW 29.76B (-8% YoY), net loss KRW 31.26B (-25% YoY)
- • Pharmaceutical distribution segment revenue decreased KRW 2.19B YoY due to market conditions; segment OP loss worsened by KRW 674M from prior year
Risk Factors
- • 10% KRW/USD exchange rate move impacts net income and equity by ±KRW 77M in FY2025
- • 10% KRW/EUR exchange rate move impacts net income and equity by ±KRW 1.4B in FY2025
Qurient FY 2025 Key Financial MetricsDART
Total Assets
KRW 62.0B
▲ +6.8% YoY
Operating Cash Flow
-KRW 28.7B
▼ -23.0% YoY
CapEx
KRW 59.9M
▲ +209.8% YoY
Source: KIFRS consolidated financial data from Qurient annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding